# A Study of Isatuximab-based Therapy in Participants With Lymphoma

> **NCT03769181** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 58 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** isatuximab SAR650984
- **DRUG:** cemiplimab REGN2810

## Key facts

- **NCT ID:** NCT03769181
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-11
- **Primary completion:** 2022-11-08
- **Final completion:** 2022-11-08
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** Study was stopped after interim analysis for all 4 cohorts with results either not fulfilling the pre-planned interim analysis criteria or fulfilling the criteria but as per sponsor decision. It was not due to any safety concern
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03769181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03769181, "A Study of Isatuximab-based Therapy in Participants With Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03769181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*